These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 32717351)

  • 1. Key considerations in the design of real-world studies.
    Fang Y; He W; Wang H; Wu M
    Contemp Clin Trials; 2020 Sep; 96():106091. PubMed ID: 32717351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Statistical Roadmap for Journey from Real-World Data to Real-World Evidence.
    Fang Y; Wang H; He W
    Ther Innov Regul Sci; 2020 Jul; 54(4):749-757. PubMed ID: 32557297
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trial designs using real-world data: The changing landscape of the regulatory approval process.
    Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two basic statistical strategies of conducting causal inference in real-world studies.
    Fang Y
    Contemp Clin Trials; 2020 Dec; 99():106193. PubMed ID: 33153972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence to support regulatory decision-making for medicines: Considerations for external control arms.
    Burcu M; Dreyer NA; Franklin JM; Blum MD; Critchlow CW; Perfetto EM; Zhou W
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1228-1235. PubMed ID: 32162381
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
    Wu J; Wang C; Toh S; Pisa FE; Bauer L
    Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When and How Can Real World Data Analyses Substitute for Randomized Controlled Trials?
    Franklin JM; Schneeweiss S
    Clin Pharmacol Ther; 2017 Dec; 102(6):924-933. PubMed ID: 28836267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
    Webster J; Smith BD
    Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reality check: Real-world evidence to support therapeutic development in hematologic malignancies.
    Derman BA; Belli AJ; Battiwalla M; Hamadani M; Kansagra A; Lazarus HM; Wang CK
    Blood Rev; 2022 May; 53():100913. PubMed ID: 35272867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
    Thompson D
    Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Practical considerations of utilizing propensity score methods in clinical development using real-world and historical data.
    Li Q; Lin J; Chi A; Davies S
    Contemp Clin Trials; 2020 Oct; 97():106123. PubMed ID: 32853779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer.
    Saesen R; Van Hemelrijck M; Bogaerts J; Booth CM; Cornelissen JJ; Dekker A; Eisenhauer EA; Freitas A; Gronchi A; Hernán MA; Hulstaert F; Ost P; Szturz P; Verkooijen HM; Weller M; Wilson R; Lacombe D; van der Graaf WT
    Eur J Cancer; 2023 Jun; 186():52-61. PubMed ID: 37030077
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case study of semaglutide and cardiovascular outcomes: An application of the C
    Dang LE; Fong E; Tarp JM; Clemmensen KKB; Ravn H; Kvist K; Buse JB; van der Laan M; Petersen M
    J Clin Transl Sci; 2023; 7(1):e231. PubMed ID: 38028337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real world evidence: An Indian perspective.
    Dang A; Vallish BN
    Perspect Clin Res; 2016; 7(4):156-160. PubMed ID: 27843789
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hybrid clinical trials to generate real-world evidence: design considerations from a sponsor's perspective.
    Zhu M; Sridhar S; Hollingsworth R; Chit A; Kimball T; Murmello K; Greenberg M; Gurunathan S; Chen J
    Contemp Clin Trials; 2020 Jul; 94():105856. PubMed ID: 31669449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. When Can Nonrandomized Studies Support Valid Inference Regarding Effectiveness or Safety of New Medical Treatments?
    Franklin JM; Platt R; Dreyer NA; London AJ; Simon GE; Watanabe JH; Horberg M; Hernandez A; Califf RM
    Clin Pharmacol Ther; 2022 Jan; 111(1):108-115. PubMed ID: 33826756
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
    Klonoff DC
    J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Real-World Data to External Control Groups in Oncology Clinical Trial Drug Development.
    Yap TA; Jacobs I; Baumfeld Andre E; Lee LJ; Beaupre D; Azoulay L
    Front Oncol; 2021; 11():695936. PubMed ID: 35070951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Using real-world evidence in haematology.
    Passamonti F; Corrao G; Castellani G; Mora B; Maggioni G; Della Porta MG; Gale RP
    Best Pract Res Clin Haematol; 2024 Mar; 37(1):101536. PubMed ID: 38490764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Augmenting control arms with real-world data for cancer trials: Hybrid control arm methods and considerations.
    Tan WK; Segal BD; Curtis MD; Baxi SS; Capra WB; Garrett-Mayer E; Hobbs BP; Hong DS; Hubbard RA; Zhu J; Sarkar S; Samant M
    Contemp Clin Trials Commun; 2022 Dec; 30():101000. PubMed ID: 36186544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.